Targets such as FAP and PSMA are combined with other therapeutic targets to treat a variety of solid tumors.
Targeted molecules are coupled with cytotoxins to reduce the limitation of radionuclide therapy in the treatment of a variety of solid tumors.
PSMA, FAP and other tumor overexpression targets are used in combination with radiolabeled therapy to treat various advanced malignant tumors, and new targets are being development continuously.
VitsGen started with PSMA and FAP targets to create best-in-class and first-in-class cancer diagnostic and therapeutic solutions, and by continuous innovation, Vitsgen aims to develop more first-in-class theranostic solutions for unmet medical needs.